Tirzepatide vs Retatrutide: Dual vs Triple Agonist Compared

Both compounds come from Eli Lilly. Both target GIP and GLP-1 receptors. The decisive question is what the glucagon receptor adds, and whether the additional efficacy justifies the years of wait for approval. The table below lays out every published comparison point.

Feature	Tirzepatide	Retatrutide
Receptor targets	GLP-1 + GIP (dual agonist)	GLP-1 + GIP + Glucagon (triple agonist)
FDA approval status	Approved: Mounjaro (T2D, 2022), Zepbound (obesity, 2023)	Investigational – no NDA submitted (as of May 2026)
Pivotal obesity trial	SURMOUNT-1: 20.9% at 72 weeks (15 mg)	TRIUMPH-1: 28.3% at 80 weeks (12 mg)
Extended weight loss	SURMOUNT-1: 22.5% at 88 weeks	TRIUMPH-1: 30.3% at 104 weeks (BMI 35+ subgroup)
Head-to-head trial	SURMOUNT-5 vs semaglutide (published)	TRIUMPH-5 vs tirzepatide (enrolling, results expected Dec 2026)
Phase 3 trials completed	SURMOUNT programme (5+ trials), SURPASS (7 trials)	TRIUMPH-1 and TRIUMPH-4 (2 of 8+ planned)
Total Phase 3 participants	10,000+ across all SURMOUNT/SURPASS trials	~5,800 across TRIUMPH programme (enrolled)
Obesity dose range	5 mg, 10 mg, 15 mg weekly	4 mg, 9 mg, 12 mg weekly (from 2 mg start)
Cardiovascular outcomes data	SURPASS-CVOT (non-inferiority vs dulaglutide)	None (TRIUMPH-3 and TRIUMPH-Outcomes pending)
Earliest possible approval	Already approved	2027-2028 (no NDA filed yet)
Legal access (May 2026)	Prescription, commercially available	Clinical trials only (grey market supply is unregulated)

The bottom line: Retatrutide produces roughly 7-8 percentage points more weight loss than tirzepatide in cross-trial comparisons, but lacks FDA approval, lacks cardiovascular outcomes data, and cannot be legally obtained outside clinical trials as of May 2026.

Retatrutide’s defining pharmacological difference is the activation of the glucagon receptor in addition to the GLP-1 and GIP receptors that tirzepatide already targets. This is not incremental – glucagon receptor activation introduces a mechanistically distinct pathway to weight loss. For full compound profiles, see the tirzepatide compound guide and the retatrutide research overview.

GLP-1 and GIP receptor activation work primarily through appetite suppression and insulin sensitivity. Glucagon does something different: it increases hepatic energy expenditure, promotes fat oxidation in the liver, and drives thermogenesis. Where tirzepatide reduces caloric intake, retatrutide’s glucagon arm also increases caloric expenditure. This dual-action on both sides of the energy balance equation is the mechanistic explanation for the efficacy gap between the two drugs.

The glucagon arm also carries potential additional benefits beyond weight loss. TRIUMPH-4 reported approximately 20% reductions in LDL cholesterol and a 72% reversal rate of prediabetes to normoglycaemia in the affected subpopulation. These cardiometabolic improvements may be partially attributable to glucagon receptor effects on hepatic lipid metabolism, which could make retatrutide particularly relevant for metabolic dysfunction-associated steatotic liver disease (MASLD) – a condition Lilly is studying in the SYNERGY programme.

The bottom line: The glucagon receptor adds increased energy expenditure and hepatic fat oxidation to the appetite suppression that GLP-1/GIP provide – retatrutide reduces intake and increases expenditure simultaneously, explaining the 7-8 percentage point weight loss advantage over tirzepatide.

The most important difference between these two compounds is not their weight loss numbers – it is the maturity and breadth of their clinical evidence.

Tirzepatide has completed multiple Phase 3 programmes across different indications: the SURMOUNT programme for obesity (including the head-to-head SURMOUNT-5 against semaglutide, published in NEJM), the SURPASS programme for type 2 diabetes (seven trials), SUMMIT for heart failure with preserved ejection fraction, SURMOUNT-OSA for obstructive sleep apnoea, and SURPASS-CVOT for cardiovascular outcomes. This body of evidence spans more than 10,000 participants across diverse populations and clinical contexts.

Retatrutide, as of May 2026, has two completed Phase 3 readouts: TRIUMPH-4 (obesity plus knee osteoarthritis, December 2025, 28.7% weight loss at 12 mg over 68 weeks) and TRIUMPH-1 (obesity without diabetes, May 2026, 28.3% at 12 mg over 80 weeks, 30.3% at 104 weeks in the BMI 35+ extension). The pivotal TRIUMPH-1 trial enrolled 2,339 participants with a mean BMI of 40.0 kg/m-squared and showed dose-dependent weight loss: 17.6% at 4 mg, 23.7% at 9 mg, and 25.0% at the primary 80-week endpoint at 12 mg, compared with 3.9% on placebo.

The 45.3% of TRIUMPH-1 participants on retatrutide 12 mg who achieved at least 30% weight loss is the figure that stops researchers – this level of pharmacological weight reduction has historically been achievable only through bariatric surgery. But these are topline results that have not yet been peer-reviewed or published in a journal. Full data including the adverse event profile, lean mass outcomes and cardiovascular markers will be presented at the ADA Scientific Sessions in June 2026.

Remaining TRIUMPH programme readouts expected in 2026 include TRIUMPH-2 (obesity plus type 2 diabetes), TRIUMPH-3 (obesity plus established cardiovascular disease), and TRIUMPH-5 (head-to-head vs tirzepatide, results expected December 2026). Long-term cardiovascular and liver outcomes trials (TRIUMPH-Outcomes and SYNERGY-Outcomes) are not expected until 2028-2029. Eli Lilly has committed $3.5 billion to manufacturing capacity expansion in anticipation of potential approval.

The bottom line: Tirzepatide has a completed regulatory dossier spanning 10,000+ participants across multiple indications; retatrutide has two strong Phase 3 readouts but no cardiovascular outcomes data, no peer-reviewed pivotal publication, and no regulatory submission yet filed.

Tirzepatide is available now by prescription in the United States, European Union, United Kingdom and numerous other markets under the brand names Mounjaro (type 2 diabetes) and Zepbound (obesity). Insurance coverage, while variable, exists across multiple payer systems. For the US regulatory framework, see the US legality overview.

Retatrutide has no submitted NDA as of May 2026. Eli Lilly has not announced a formal submission date, though regulatory filings are anticipated following the completion of additional Phase 3 readouts expected through 2026. Realistically, FDA approval before 2027-2028 is unlikely given the standard review timeline after submission. The European Medicines Agency agreed on a Paediatric Investigation Plan in September 2024, requiring evaluation in adolescents aged 12-17, which suggests Lilly is preparing for a global filing strategy.

Retatrutide appearing on grey market research peptide sites does not constitute legal access. These products are not FDA-regulated, not manufactured to pharmaceutical standards, and carry unknown purity and contamination risks that are particularly acute for an investigational compound with no regulatory reference standard.

The bottom line: Tirzepatide can be prescribed today; retatrutide is 18-24 months from the earliest possible approval, and any current grey market supply carries significant quality and safety risks.

Tirzepatide’s safety profile is well-characterised across thousands of patients and multiple completed trials. The dominant adverse events are gastrointestinal (nausea, diarrhoea, constipation), generally mild to moderate, concentrated during dose escalation, and rarely cause discontinuation. Tirzepatide carries standard class warnings for thyroid C-cell tumours and pancreatitis risk.

Retatrutide’s safety data is still accumulating. In TRIUMPH-4, gastrointestinal side effects were observed but described as “generally mild and infrequently led to discontinuation.” The full TRIUMPH-1 adverse event profile has not yet been published (expected at ADA June 2026). The glucagon receptor activation introduces a theoretical concern around blood glucose elevation that is not present with tirzepatide, though TRIUMPH-1 enrolled participants without diabetes. How retatrutide performs in the type 2 diabetes population (TRIUMPH-2) and cardiovascular disease population (TRIUMPH-3) will be critical safety data points.

Novo Nordisk’s competing candidate CagriSema (semaglutide plus cagrilintide) failed to outperform Zepbound in a Phase 3 head-to-head readout in February 2026, and Novo’s high-dose Wegovy (7.2 mg) produced 27.7% weight loss but only in an early-responder subset. For context on where semaglutide fits in this landscape, see semaglutide vs tirzepatide.

The bottom line: Tirzepatide has a well-characterised safety profile from thousands of patients; retatrutide’s safety data is promising but incomplete, with the full adverse event analysis from TRIUMPH-1 not yet published.

The clinical answer for most people eligible for obesity pharmacotherapy is no. Tirzepatide is available now, produces clinically meaningful weight loss (20%+ in trials), and has years of safety data. Delaying treatment by 18-24 months to wait for a drug that delivers an additional 7-8 percentage points of weight loss means living with the metabolic and cardiovascular consequences of obesity for that entire period. Obesity-related comorbidities do not pause while waiting for regulatory approvals.

The more realistic framing is sequential: start tirzepatide (or semaglutide) now, and switch to retatrutide after approval if the additional efficacy is clinically meaningful for the individual patient’s situation. The TRIUMPH-5 head-to-head trial comparing retatrutide directly against tirzepatide (results expected December 2026) will provide the data needed to evaluate whether the glucagon receptor addition justifies a switch for patients already achieving meaningful weight loss on tirzepatide.

For the subset of patients who respond poorly to both semaglutide and tirzepatide – potentially due to GLP-1 receptor biology as suggested by recent genetic research – retatrutide’s glucagon receptor mechanism offers a mechanistically distinct pathway that might produce a response where GLP-1-only approaches have failed. This is speculative until confirmed by clinical data, but it represents the most compelling clinical rationale for the triple-agonist approach.

Is retatrutide just tirzepatide with an extra receptor?

Not exactly. Both are Lilly products and both activate GLP-1 and GIP receptors, but retatrutide is a distinct molecule with different binding affinities and signalling dynamics at each receptor. The glucagon receptor activation introduces an entirely new metabolic pathway (hepatic energy expenditure and fat oxidation) that tirzepatide does not engage. The receptor overlap is real, but they are structurally and pharmacologically different drugs.

When will the head-to-head trial between tirzepatide and retatrutide report?

TRIUMPH-5, the direct randomised comparison, is currently enrolling with results expected by the end of 2026. This will be the first trial to eliminate cross-trial comparison limitations and provide definitive head-to-head efficacy data. Until TRIUMPH-5 reports, the 7-8 percentage point gap is an estimate based on comparing TRIUMPH-1 and SURMOUNT-1, which used different populations and durations.

Is the 30.3% weight loss figure for retatrutide reliable?

The 30.3% figure comes from the TRIUMPH-1 pre-specified blinded extension in participants with a baseline BMI of 35 or higher who continued on the highest dose to 104 weeks. It is a subgroup analysis, not the primary endpoint for the full trial population (see the comparison table above for the primary result). Both figures are topline data announced via press release (21 May 2026) and have not yet been peer-reviewed. Full data publication is expected at ADA June 2026.

Can I buy retatrutide from research peptide vendors?

Retatrutide appears on grey market research peptide sites, but these products are unregulated, not manufactured to pharmaceutical Good Manufacturing Practice standards, and carry unknown purity and contamination profiles. Unlike tirzepatide and semaglutide (which have been through FDA approval and have defined manufacturing specifications), retatrutide has no regulatory reference standard to compare against. Any grey market retatrutide product could contain anything. For the framework on evaluating peptide sourcing risks, see the vendor assessment guide.